A joint program between EPFL Innovation Park and Groupe Mutuel
Call for Application 2022 Opening soon!
Next Roadshow November 17th
Program Duration 9 months
June 12, 2024

Announcing Our New Partnership with Debiotech

Debiotech Prize to drive women’s health innovation

Tech4Eva is happy to announce a strategic partnership with Debiotech, a leading service development company dedicated to innovation in medical technology for over 30 years. This collaboration marks a significant step in advancing Femtech innovation and supporting start-ups, as well as other players, in the development of transformative healthcare solutions. The partnership with Tech4Eva underscores Debiotech's commitment to advancing Femtech innovation and addressing the unique healthcare needs of women.

About Debiotech

Debiotech has established itself as a pioneer in the field of medical technology, consistently bridging the gap between conceptual ideas and technological implementation. The company has recently undergone a strategic transition in its business model. While traditionally focused on developing proprietary medical products, the company has evolved to become a leading provider of engineering services for innovative ventures. Leveraging its expertise in developing complete medical devices, Debiotech now focuses on collaboration and partnerships, offering start-ups and other companies access to specialized engineering support, accelerating their path to market.

Their multi-disciplinary team of experts specializes in designing complex medical devices for regulated markets, ensuring that each product meets the highest standards of quality and safety. Adapting to the rapidly evolving needs, requirements, and regulatory constraints of the Medtech industry, Debiotech employs an agile methodology. This approach allows them to deliver tailor-made solutions efficiently, without compromising on quality. Their commitment to excellence is underscored by their ISO 13485 certification and adherence to QMS standards, including FDA 21 CFR Part 820 and MDR requirements, as well as ISO/IEC 62304, 60601-1, 62366, and 14971.

A New Opportunity for Innovation

The inaugural Debiotech Prize, awarded during Tech4Eva's Opening Ceremony on May 13th,exemplifies the company's dedication to supporting start-ups and other players in their development efforts. This prize, consisting of CHF 100,000 in in-kind support from Debiotech's engineering team, recognizes innovative companies with products that significantly improve patient outcomes. Ablatus - creators of Luna was awarded the Debiotech Prize for its Luna device, designed to revolutionize the treatment of uterine fibroids.

"This exemplifies our dedication to recognizing and supporting innovative companies with products that have the potential to revolutionize patient care. It marks the beginning of an exciting journey to empower the next generation of healthcare leaders" comments Laurent-Dominique Piveteau, CEO of Debiotech.

Chung Looi, CEO of Ablatus added: "We at Ablatus are very proud and delighted to be the Winner of the Debiotech Prize 2024. We look forward to a successful collaboration with the exceptional and highly experienced team at Debiotech to accelerate the development and deliver the impact of our patented technology. We aim to bring a new treatment option that is minimally invasive, uterus- preserving, and more inclusive to millions of women suffering from the debilitating symptoms of uterine fibroids globally within the next few years."

Debiotech remains steadfast in its commitment to driving innovation and supporting the development of transformative healthcare solutions for start-ups, other Medtech innovative players, and on top of it to improve patients’ quality of life worldwide.

Laurent-Dominique Piveteau, CEO of Debiotech, expressed his enthusiasm about the selection of the prize winner: "The project by Ablatus impressed us with the elegance of its solution and the real benefit it represents for patients suffering from a very disabling condition. This project is perfectly in line with what has driven the company for over 30 years: patient-centered innovation. But we would also like to congratulate all the candidates for the Debiotech Prize. The high quality of the projects identified by Tech4Eva made our selection task particularly difficult."

Laurent-Dominique Piveteau, CEO of Debiotech and Chung Looi, CEO of Ablatus

Celebrating Innovation and Collaboration

At Tech4Eva, we are deeply committed to advancing Femtech innovation, recognizing the unique healthcare needs of women and the importance of specialized solutions. Our partnership with Debiotech brings invaluable expertise and resources to our community. Debiotech’s extensive experience in developing sophisticated medical devices will significantly bolster our efforts to support Femtech start-ups, helping them navigate the complexities of product development and regulatory compliance.

This collaboration aims to drive transformative advancements in women’s health, ensuring that innovative solutions reach the market efficiently and safely. We look forward to seeing the remarkable advancements that Ablatus and other participating start-ups will achieve with the support of Debiotech.

Stay tuned for more updates on our partnership with Debiotech.

More info on Debiotech: https://www.debiotech.com/